Going back to work check for employers

Recent studies suggest that a high percentage of patients show no clinical symptoms of the virus, which makes screening patients vitally important. The test can be used for rapid screening of carriers of the virus that are symptomatic or asymptomatic. By using biomarkers from the body’s immune response to COVID-19 instead of looking for the virus itself, the test can help determine if a person has been infected with COVID-19 even after the virus is no longer present. This information helps experts to better understand how the virus spreads through populations and develop strategies to prevent and slow the epidemic. The test is ideally suited for businesses.


Quadratech’s new rapid IgM-IgG combined antibody test for COVID-19 has been used widely by the French authorities to combat infections and is now available globally. Quadratech has also received CE Mark-IVD certification for the test which will allow it to be used to help diagnose patients in areas of Europe that have been impacted by the appearance of the COVID-19 pathogen.

IgM antibodies are usually the first antibody produced by the immune system when a virus attacks. A positive IgM test indicates that you may have been infected and that your immune system has started responding to the virus.  When IgM is detected you may still be infected, or you may have recently recovered from a COVID-19 infection.

IgG antibodies develop in most patients within seven to 10 days after symptoms of COVID-19 begin. IgG antibodies remain in the blood after an infection has passed. These antibodies indicate that you may have had COVID-19 in the recent past and have developed antibodies that may protect you from future infection. It is unknown at this point how much protection antibodies might provide against reinfection.

Fig.1 – Approximate IgM and IgG antibody levels over time – Not actual data – for illustration purposes only

COVID-19-CHECK-1 IgG/IgM Cassette (CE Marked) 10min Whole Blood/Serum/Plasma) is a rapid immunochromatographic screening test for the qualitative detection of the anti-SARS-CoV-2 IgG/IgM antibodies in serum, plasma or whole blood.

It is intended to be used by medical healthcare professionals as a tool to assess the COVID-19 serological status of people and cannot be directly used to diagnose a coronavirus 2019 infection (COVID-19). 

The method relies on a mixture of recombinant SARS-CoV-2 antigens labeled with gold particles and anti-human IgM and IgG antibodies bound to the membrane solid phase. The multiple epitope fusion SARS-CoV-2 proteins are produced synthetically according to the genetic information of the virus. This material is therefore 100% non-infectious. 

What are the possible results? 

IgM POSITIVE:* Two lines appear. One coloured line should be in the control line region (C), and a coloured line appears in IgM test line region (T1). The result suggests the sample contains IgM antibodies specific to the SARS-CoV-2 and indicates a primary/recent infection.

IgG POSITIVE:* Two lines appear. One coloured line should be in the control line region (C), and a coloured line appears in IgG test line region (T2). The result suggests the sample contains IgG antibodies specific to the SARS-CoV-2 and may indicate a secondary infection or late stage of the disease.

IgG and IgM POSITIVE:* Three lines appear. One coloured line should be in the control line region (C), and two coloured lines should appear in the IgM test line region (T1) and the IgG test line region (T2). The colour intensities of the lines do not have to match. The result suggests the sample contains both IgM and IgG antibodies specific to the SARS-CoV-2 and may indicate an active or a secondary infection.

What is the difference between Primary SARS-CoV-2 infection and Secondary SARS-CoV-2 infection? 

Primary SARS-CoV-2 infection is characterised by the presence of detectable IgM antibodies approximately 8 – 11 days* post infection. 

Secondary SARS-CoV-2 infection is characterized by the elevation of SARS-CoV-2 specific IgG. In the majority of the cases, this is accompanied by elevated levels of IgM.

What samples are required to run the test? 

The test works with whole blood from a finger prick. It can also be used with serum and plasma in laboratory settings. 

What is the testing time? 

The test result should be read between 10 to 15 minutes after adding the diluent. 

Contact us for an appointment at the clinic or at your place of work (subject to availability)

0207 436 9672

admin@forma.co.uk

www.forma.co.uk